Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Acquired by First Horizon Advisors Inc.

First Horizon Advisors Inc. increased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 24.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,491 shares of the biopharmaceutical company’s stock after acquiring an additional 293 shares during the period. First Horizon Advisors Inc.’s holdings in Halozyme Therapeutics were worth $55,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Advisors Asset Management Inc. boosted its position in shares of Halozyme Therapeutics by 0.6% in the third quarter. Advisors Asset Management Inc. now owns 45,598 shares of the biopharmaceutical company’s stock worth $1,742,000 after buying an additional 287 shares during the period. Fifth Third Bancorp grew its stake in Halozyme Therapeutics by 2.6% during the 3rd quarter. Fifth Third Bancorp now owns 12,262 shares of the biopharmaceutical company’s stock valued at $468,000 after acquiring an additional 308 shares in the last quarter. Commonwealth Equity Services LLC grew its stake in Halozyme Therapeutics by 2.2% during the 3rd quarter. Commonwealth Equity Services LLC now owns 16,216 shares of the biopharmaceutical company’s stock valued at $619,000 after acquiring an additional 347 shares in the last quarter. Truist Financial Corp increased its holdings in shares of Halozyme Therapeutics by 0.6% in the 4th quarter. Truist Financial Corp now owns 102,622 shares of the biopharmaceutical company’s stock valued at $3,793,000 after purchasing an additional 563 shares during the period. Finally, Alliance Wealth Advisors LLC UT lifted its position in shares of Halozyme Therapeutics by 7.4% in the third quarter. Alliance Wealth Advisors LLC UT now owns 8,389 shares of the biopharmaceutical company’s stock worth $320,000 after purchasing an additional 581 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Stock Performance

HALO opened at $41.21 on Wednesday. The stock has a 50-day moving average of $40.04 and a 200-day moving average of $37.99. The company has a debt-to-equity ratio of 17.89, a quick ratio of 5.50 and a current ratio of 6.64. Halozyme Therapeutics, Inc. has a 52-week low of $29.85 and a 52-week high of $45.00. The company has a market cap of $5.24 billion, a PE ratio of 19.53, a price-to-earnings-growth ratio of 0.47 and a beta of 1.26.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. The company had revenue of $230.04 million for the quarter, compared to the consensus estimate of $235.25 million. As a group, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 3.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have weighed in on HALO shares. TD Cowen initiated coverage on shares of Halozyme Therapeutics in a research note on Thursday, February 29th. They issued an “outperform” rating and a $54.00 price objective on the stock. JMP Securities reiterated a “market outperform” rating and set a $72.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday, February 21st. The Goldman Sachs Group lowered their target price on Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating on the stock in a research note on Thursday, January 18th. Benchmark reaffirmed a “buy” rating and set a $50.00 price target on shares of Halozyme Therapeutics in a research note on Tuesday, April 16th. Finally, TheStreet cut Halozyme Therapeutics from a “b-” rating to a “c+” rating in a research note on Monday, January 22nd. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $53.29.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $41.64, for a total transaction of $416,400.00. Following the completion of the transaction, the senior vice president now owns 156,558 shares of the company’s stock, valued at approximately $6,519,075.12. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last three months, insiders have sold 30,000 shares of company stock worth $1,196,800. 2.70% of the stock is owned by insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.